Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Chimeric Therapeutics Ltd. ( (AU:CHM) ).
Chimeric Therapeutics Ltd. has notified the market of the issue of 10,000,000 unquoted options, exercisable at $0.50 and expiring on 31 December 2030. These securities, issued on 4 May 2026 under code CHMAAI, form part of a previously announced transaction and are not intended to be quoted on the ASX, signaling a structured equity incentive or funding mechanism for the company.
The new unquoted options may serve to align key stakeholders with Chimeric Therapeutics’ long-term value creation and clinical development milestones. By expanding its pool of long-dated equity incentives, the company reinforces its capital management strategy while limiting immediate dilution for ordinary shareholders, which could support its competitiveness in the biotech sector.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. is an Australian biotechnology company listed on the ASX under the ticker CHM. The company operates in the biopharmaceutical and cell therapy sector, focusing on developing innovative therapeutic products, likely targeting oncology and other serious diseases through advanced treatment modalities.
Average Trading Volume: 220,497
Technical Sentiment Signal: Sell
Current Market Cap: A$7.29M
For an in-depth examination of CHM stock, go to TipRanks’ Overview page.